Renaud Schiappa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Renaud Schiappa has a total of 404 co-authors. Here are the top co-authors by number of shared publications:
- Dorian Culié
Centre Antoine Lacassagne, Institut Universitaire de la Face et du Cou, Nice, France
10 shared publications - Emmanuel Chamorey
Department of Statistics, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France
9 shared publications - Jean-Michel Hannoun-Levi
Department of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d'Azur, Nice, France
8 shared publications Emmanuel Chamorey
Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
7 shared publicationsJocelyn Gal
Department of Statistics, Antoine Lacassagne Cancer Center - University of Côte d'Azur, Nice, France
7 shared publications- Tanguy Pace-Loscos
Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne University of Côte d'Azur Nice France
7 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1619-1628
Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly ( HALO trial)
Summary: The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL. The prospective, open‐label, phase I/II Hodgkin lymphoma combining Adcetris® and Levact® in Old patients (HALO) study was launched (Clinical Trial.Gov Id. 02467946) to test safety and efficacy of Be‐BV in untreated eHL. The mean age was 70.75 (62–79), stage IIB in 12, III in 14 and IV in 31 patients. Most had B‐symptoms and an International Prognostic Score (IPS) ≥3 (39). Despite a good performance status and both a high activity of daily living (ADL) (≥6 in 85%) and instrumental activities of daily living (IADL) scores (≥8 in 77%), 68% of patients had ≥5 comorbidities, with a Cumulative Illness Rating Scale‐Geriatric (CIRS)‐G score >3 in 75%. A complete metabolic response (CMR) was achieved in 44/57 of patients. The 6‐year overall survival (OS) and progression‐free survival (PFS) in per‐protocol (PP) analysis were 67% (95% confidence intertvals [CI] 53–84) and 45% (95% CI 32–65) respectively. A PFS event was observed in 35: 13 progressions (10 deaths), 13 relapses (6 deaths) and 9 deaths. Be‐BV, when given in a full dose schedule, is an effective regimen for unselected, poor‐risk elderly Hodgkin lymphoma (HL) patients.
- 26 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1619-1628
Open AccessLong‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly ( HALO trial)
Summary: The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL. The prospective, open‐label, phase I/II Hodgkin lymphoma combining Adcetris® and Levact® in Old patients (HALO) study was launched (Clinical Trial.Gov Id. 02467946) to test safety and efficacy of Be‐BV in untreated eHL. The mean age was 70.75 (62–79), stage IIB in 12, III in 14 and IV in 31 patients. Most had B‐symptoms and an International Prognostic Score (IPS) ≥3 (39). Despite a good performance status and both a high activity of daily living (ADL) (≥6 in 85%) and instrumental activities of daily living (IADL) scores (≥8 in 77%), 68% of patients had ≥5 comorbidities, with a Cumulative Illness Rating Scale‐Geriatric (CIRS)‐G score >3 in 75%. A complete metabolic response (CMR) was achieved in 44/57 of patients. The 6‐year overall survival (OS) and progression‐free survival (PFS) in per‐protocol (PP) analysis were 67% (95% confidence intertvals [CI] 53–84) and 45% (95% CI 32–65) respectively. A PFS event was observed in 35: 13 progressions (10 deaths), 13 relapses (6 deaths) and 9 deaths. Be‐BV, when given in a full dose schedule, is an effective regimen for unselected, poor‐risk elderly Hodgkin lymphoma (HL) patients.
- Open Access
- 11 August 2026
- Published by Elsevier in The Breast
- Vol. 89, 104895
Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database
- 11 August 2026
- Published by Elsevier in The Breast
- Vol. 89, 104895
Open AccessLocal treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database
- 8 August 2025
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 313, 114622
Therapeutic impact of eras protocol implementation in cytoreductive surgery for ovarian cancer
- 8 August 2025
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 313, 114622
Therapeutic impact of eras protocol implementation in cytoreductive surgery for ovarian cancer
- 27 April 2025
- Published by Springer Nature
- p. 19-41
Fed-BioMed: Open, Transparent and Trusted Federated Learning for Real-world Healthcare Applications
- 27 April 2025
- Published by Springer Nature
- p. 19-41
Fed-BioMed: Open, Transparent and Trusted Federated Learning for Real-world Healthcare Applications
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2300263
Enhancing Thyroid Pathology With Artificial Intelligence: Automated Data Extraction From Electronic Health Reports Using RUBY
PURPOSE: Thyroid nodules are common in the general population, and assessing their malignancy risk is the initial step in care. Surgical exploration remains the sole definitive option for indeterminate nodules. Extensive database access is crucial for improving this initial assessment. Our objective was to develop an automated process using convolutional neural networks (CNNs) to extract and structure biomedical insights from electronic health reports (EHRs) in a large thyroid pathology cohort. MATERIALS AND METHODS: We randomly selected 1,500 patients with thyroid pathology from our cohort for model development and an additional 100 for testing. We then divided the cohort of 1,500 patients into training (70%) and validation (30%) sets. We used EHRs from initial surgeon visits, preanesthesia visits, ultrasound, surgery, and anatomopathology reports. We selected 42 variables of interest and had them manually annotated by a clinical expert. We developed RUBY-THYRO using six distinct CNN models from SpaCy, supplemented with keyword extraction rules and postprocessing. Evaluation against a gold standard database included calculating precision, recall, and F1 score. RESULTS: Performance remained consistent across the test and validation sets, with the majority of variables (30/42) achieving performance metrics exceeding 90% for all metrics in both sets. Results differed according to the variables; pathologic tumor stage score achieved 100% in precision, recall, and F1 score, versus 45%, 28%, and 32% for the number of nodules in the test set, respectively. Surgical and preanesthesia reports demonstrated particularly high performance. CONCLUSION: Our study successfully implemented a CNN-based natural language processing (NLP) approach for extracting and structuring data from various EHRs in thyroid pathology. This highlights the potential of artificial intelligence-driven NLP techniques for extensive and cost-effective data extraction, paving the way for creating comprehensive, hospital-wide data warehouses.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2300263
Enhancing Thyroid Pathology With Artificial Intelligence: Automated Data Extraction From Electronic Health Reports Using RUBY
PURPOSE: Thyroid nodules are common in the general population, and assessing their malignancy risk is the initial step in care. Surgical exploration remains the sole definitive option for indeterminate nodules. Extensive database access is crucial for improving this initial assessment. Our objective was to develop an automated process using convolutional neural networks (CNNs) to extract and structure biomedical insights from electronic health reports (EHRs) in a large thyroid pathology cohort. MATERIALS AND METHODS: We randomly selected 1,500 patients with thyroid pathology from our cohort for model development and an additional 100 for testing. We then divided the cohort of 1,500 patients into training (70%) and validation (30%) sets. We used EHRs from initial surgeon visits, preanesthesia visits, ultrasound, surgery, and anatomopathology reports. We selected 42 variables of interest and had them manually annotated by a clinical expert. We developed RUBY-THYRO using six distinct CNN models from SpaCy, supplemented with keyword extraction rules and postprocessing. Evaluation against a gold standard database included calculating precision, recall, and F1 score. RESULTS: Performance remained consistent across the test and validation sets, with the majority of variables (30/42) achieving performance metrics exceeding 90% for all metrics in both sets. Results differed according to the variables; pathologic tumor stage score achieved 100% in precision, recall, and F1 score, versus 45%, 28%, and 32% for the number of nodules in the test set, respectively. Surgical and preanesthesia reports demonstrated particularly high performance. CONCLUSION: Our study successfully implemented a CNN-based natural language processing (NLP) approach for extracting and structuring data from various EHRs in thyroid pathology. This highlights the potential of artificial intelligence-driven NLP techniques for extensive and cost-effective data extraction, paving the way for creating comprehensive, hospital-wide data warehouses.
- 28 October 2024
- Published by Elsevier in Oral Oncology
- Vol. 159, 107082
Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas
- 28 October 2024
- Published by Elsevier in Oral Oncology
- Vol. 159, 107082
Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas
- Open Access
Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation
The aim of this study was to assess the potential value of circulating active and inactive IL-18 levels in distinguishing pseudo and true tumor progression among NSCLC patients receiving immune checkpoint inhibitor treatments (ICIs). Methods: This ancillary study includes 195 patients with metastatic non-small-cell lung cancer (NSCLC) treated with ICI in monotherapy, either pembrolizumab or nivolumab. Plasmatic levels of IL-18-related compounds, comprising the inhibitor IL-18 binding protein (IL-18BP), the inactive IL-18 (corresponding to IL-18/IL-18BP complex), and the active free IL-18, were assayed by ELISA. Objective tumoral response was analyzed by 18FDG PET-CT at baseline, 7 weeks, and 3 months post treatment induction, using PERCIST criteria. Results: Plasmatic IL-18BP and total IL-18 levels are increased at baseline in NSCLC patients compared with healthy controls, whereas IL-18/IL-18BP complexes are decreased, and free IL-18 levels remain unchanged. Neither of the IL-18-related compounds allowed to discriminate ICI responding to nonresponding patients. However, inactive IL-18 levels allowed to discriminate patients with a first tumor progression, assessed after 7 weeks of treatment, with worse overall survival. In addition, we showed that neutrophil concentration is also a predictive indicator of patients’ outcomes with OS (HR = 2.6, p = 0.0001) and PFS (HR = 2.2, p = 0.001). Conclusions: Plasmatic levels of inactive IL-18, combined with circulating neutrophil concentrations, can effectively distinguish ICI nonresponding patients with better overall survival (OS), potentially guiding rapid decisions for therapeutic intensification.
Open AccessPlasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation
The aim of this study was to assess the potential value of circulating active and inactive IL-18 levels in distinguishing pseudo and true tumor progression among NSCLC patients receiving immune checkpoint inhibitor treatments (ICIs). Methods: This ancillary study includes 195 patients with metastatic non-small-cell lung cancer (NSCLC) treated with ICI in monotherapy, either pembrolizumab or nivolumab. Plasmatic levels of IL-18-related compounds, comprising the inhibitor IL-18 binding protein (IL-18BP), the inactive IL-18 (corresponding to IL-18/IL-18BP complex), and the active free IL-18, were assayed by ELISA. Objective tumoral response was analyzed by 18FDG PET-CT at baseline, 7 weeks, and 3 months post treatment induction, using PERCIST criteria. Results: Plasmatic IL-18BP and total IL-18 levels are increased at baseline in NSCLC patients compared with healthy controls, whereas IL-18/IL-18BP complexes are decreased, and free IL-18 levels remain unchanged. Neither of the IL-18-related compounds allowed to discriminate ICI responding to nonresponding patients. However, inactive IL-18 levels allowed to discriminate patients with a first tumor progression, assessed after 7 weeks of treatment, with worse overall survival. In addition, we showed that neutrophil concentration is also a predictive indicator of patients’ outcomes with OS (HR = 2.6, p = 0.0001) and PFS (HR = 2.2, p = 0.001). Conclusions: Plasmatic levels of inactive IL-18, combined with circulating neutrophil concentrations, can effectively distinguish ICI nonresponding patients with better overall survival (OS), potentially guiding rapid decisions for therapeutic intensification.
- Open Access
- 3 June 2024
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 4
Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)
- 3 June 2024
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 4
Open AccessReal-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)
- Open Access
- 31 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6058
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes. However, a significant association between higher AA concentrations and better clinical benefit was observed (p = 0.041). The safety data did not correlate with the AA PK data. A significant positive correlation (r = 0.40, p < 0.001) was observed between mean AA concentration and patient age: the older the patient, the higher the AA concentration. Patient age was found to impact steady-state AA concentration: the older the patient, the higher the mean AA concentration. Altogether, these data may help to guide future research and clinical trials in order to maximize the benefits of AA metastatic castration-resistant prostate cancer patients.
- 31 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6058
Open AccessLong-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes. However, a significant association between higher AA concentrations and better clinical benefit was observed (p = 0.041). The safety data did not correlate with the AA PK data. A significant positive correlation (r = 0.40, p < 0.001) was observed between mean AA concentration and patient age: the older the patient, the higher the AA concentration. Patient age was found to impact steady-state AA concentration: the older the patient, the higher the mean AA concentration. Altogether, these data may help to guide future research and clinical trials in order to maximize the benefits of AA metastatic castration-resistant prostate cancer patients.
- 7 March 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 194, 110217
Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort
- 7 March 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 194, 110217
Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort